The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

ALLO FINANCIAL STATEMENTS

Allogene Therapeutics Inc — balance sheet, income statement and cash flow trends

ALLOAllogene Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-200 M0202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue4.6 M $Gross Profit-32.5 M $ · -699%Operating Income-180.3 M $ · -3886%Pre-tax Income-165.5 M $ · -3567%Net Income to Owners-165.5 M $ · -3567%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue4.6 M $—
Gross Profit-32.5 M $—
Operating Income-180.3 M $—
EBITDA-152.5 M $—
Net Income to Owners-165.5 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0500 M1 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets550.1 M
  • Equity436.2 M $79%
  • Current Liabilities31.7 M $6%
  • Long-term Liabilities82.2 M $15%

Key Figures

YoY change
Total Assets550.1 M $+16.9%
Total Liabilities113.9 M $-9.6%
Total Equity436.2 M $+26.6%
Cash & ST Investments332.6 M $+21.8%
Total Debt70.4 M $-11.2%
Net Debt31.7 M $+17.9%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-200 M-100 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-200 M-100 M0-102.2 M $Operating-131.6 M $Investing220.1 M $Financing-13.7 M $Net Change

Key Figures

YoY change
Operating Cash Flow-102.2 M $—
Capital Expenditures402 K $-51.5%
Free Cash Flow-102.6 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ALLO

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.